Document Detail

Molecular prediction of progression in patients with conservatively managed prostate cancer.
MedLine Citation:
PMID:  11711356     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To report our results with the use of reverse transcriptase-polymerase chain reaction (RT-PCR) as a potential predictor of prostate cancer (CaP) progression in patients managed with watchful waiting. There has been much recent debate about the safety of treating older patients with localized CaP with watchful waiting. The RT-PCR is an assay that can detect small numbers of prostate cells in circulating blood. METHODS: Blood samples were taken from male and female control patients and from patients with advanced, hormone-treated and untreated localized (watchful-waiting) CaP. Sensitive nested RT-PCR assays were carried out on these samples using primers for both prostate-specific antigen (PSA) and prostate-specific membrane antigen mRNA. RESULTS: Fifty-one blood samples were taken from patients managed with watchful waiting. Fourteen of these had positive RT-PCR results. These patients had a significantly higher PSA velocity than did the patients with negative RT-PCR results. Circulating prostate cells were detected in 18 of 24 patients with advanced CaP, 2 of 34 patients with stable, hormone-treated CaP, and in none of the negative controls. The assay was able to detect 20 LNCaP cells reliably when added to a 5-mL volunteer blood sample. CONCLUSIONS: A significant minority (27%) of patients with untreated localized CaP had detectable circulating prostate cells, and these patients tended to have a progressively rising serum PSA level. Despite low-grade disease and sometimes low serum PSA values, these patients may be at risk of early metastatic progression. RT-PCR, in conjunction with existing prognostic tests, may be of use in predicting which "watchful-waiting" patients are at risk of early progression.
I G McIntyre; R B Clarke; E Anderson; N W Clarke; N J George
Related Documents :
709516 - Circulating carcinoembryonic antigen in pancreatic carcinoma.
9351306 - Is intravenous urography still used in patients with prostatism?
2898556 - Steroid metabolism in testes of patients with incomplete masculinization due to androge...
9337536 - Cea, nse and scc ag in bronchial lavage in patients with lung cancer.
22402306 - Tubular markers are associated with decline in kidney function in proteinuric type 2 di...
1810836 - Cardiovascular reflexes and pudendal evoked responses in chronic haemodialysis patients.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Urology     Volume:  58     ISSN:  1527-9995     ISO Abbreviation:  Urology     Publication Date:  2001 Nov 
Date Detail:
Created Date:  2001-11-16     Completed Date:  2001-12-13     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  762-6     Citation Subset:  IM    
Department of Urology, University Hospital of South Manchester, Withington Hospital, Manchester, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Disease Progression
Neoplastic Cells, Circulating* / pathology
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / blood*,  pathology
Reverse Transcriptase Polymerase Chain Reaction*
Sensitivity and Specificity
Reg. No./Substance:
EC Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men wi...
Next Document:  Early evolution of bladder emptying after myelomeningocele closure.